Study type

Study topic

Human medicinal product
Disease /health condition

Study type

Non-interventional study

Scope of the study

Other

If ‘other’, further details on the scope of the study

Case series review of Pharmacovigilance data

Data collection methods

Secondary use of data
Non-interventional study

Non-interventional study design

Other

Non-interventional study design, other

Case-series
Study drug and medical condition

Study drug International non-proprietary name (INN) or common name

CITALOPRAM
FLUOXETINE
FLUVOXAMINE
PAROXETINE
PAROXETINE ACETATE
SERTRALINE
DESVENLAFAXINE
FLUOXETINE HYDROCHLORIDE
PHENTERMINE HYDROCHLORIDE
OLANZAPINE

Medical condition to be studied

Loss of libido
Genital hypoaesthesia
Libido decreased
Female sexual arousal disorder
Anorgasmia
Female orgasmic disorder
Male orgasmic disorder

Additional medical condition(s)

Post-SSRI Sexual Dysfunctions
Population studied

Short description of the study population

Case reports of persistent sexual dysfunctions to Serotonin and norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors and other antidepressants.

Age groups

Children (2 to < 12 years)
Adolescents (12 to < 18 years)
Adults (18 to < 46 years)
Adults (46 to < 65 years)
Adults (65 to < 75 years)
Adults (75 to < 85 years)
Adults (85 years and over)

Estimated number of subjects

3210
Study design details

Main study objective

Describe cases of Post-SSRI sexual dysfunction

Data analysis plan

Descriptive statistics were run on the totality of the cases with sexual dysfunctions, by reporter type, by substance, by class, by indication, by country, by age, gender and by previous medical history of sexual dysfunction. Results by reaction were stratified by core PSSD case definition (see 4.3.2.), extended terms definition, which are the remaining terms from the sexual dysfunction case definition (see 4.3.1.) and secondary terms as per annex II.
Documents
Study results
English (899.54 KB - PDF)View document